Immunis has enlisted the services of Springbok Analytics in its Phase I/II clinical trial for a sarcopenia therapy, leveraging the company’s MRI-based AI muscle analysis technology.
US-based Springbok’s technology can quantify individual muscles based on MRI. The scan provides insights into muscle health and muscle development.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Immunis said the technology will be used to see how its Immuna therapy alters tissue architecture and function. The platform analyses MRI data and creates a three-dimensional visualisation of musculoskeletal health.
Immunis scientific communications manager Dr Karissa Muñoz said: “We are relying on Springbok to better understand the biological efficacy of our potentially groundbreaking secretome therapy.”
Immuna is a therapy based on human cell-derived secretions with the addition of natural factors. Specifically, it is derived from partially differentiated pluripotent cells concentrated with regenerative molecules. This so-called secretome is currently being investigated in sarcopenic populations – those with age-related muscle loss.
Immunis is nearing the completion of a Phase I/II clinical trial, which is testing the safety, tolerability, and efficacy of Immuna in reversing muscle atrophy in an aged population with knee osteoarthritis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe single-centre, open-label, dose-escalation study will see Immuna administered via intramuscular injection twice per week for four weeks. The study is being conducted at the University of California’s Irvine Medical Center.
Springbok’s lower extremity scan can be done in under ten minutes, with a full body scan taking an extra half an hour.
Immunis director of medical affairs Erin Curry said: “Springbok is essential to our analytical pipeline as we process and critically assess the clinical trial data we are gathering in our efforts to reverse various aspects of ageing.”
Sarcopenia treatment is a hot market, as restoring muscle growth in function can help limit disability in elderly adults. Immunis states the condition accounts for more than $40bn in annual healthcare costs in the US.
Biophytis reported positive Phase II results for its sarcopenia treatment Ruvembri (20-hydroxyecdysone). The French company unveiled its Phase III protocol in March this year. Biophytis CEO Stanislas Veillet said at the time that “after receiving approval to initiate [the Phase III study] in Belgium and the United States, our drug candidate appears to be the most advanced in this indication”.
